Known safety concerns, contraindications, and risk factors.
Pregnancy or breastfeeding
No reproductive safety data exists for AOD-9604. The compound has not been tested in pregnant or lactating populations.
Active malignancy
While AOD-9604 does not raise IGF-1, its demonstrated ability to stimulate chondrocyte proliferation suggests non-IGF-1 growth signalling pathways.
Pediatric use
No safety or efficacy data exists for individuals under 18. Effects on developing endocrine and metabolic systems are unknown.
Diabetes, thyroid disorders, or cardiovascular disease
While AOD-9604 does not disrupt glucose or cause fluid retention, patients with metabolic comorbidities require monitoring. The compound's effects in these populations are unstudied.
Active joint infection or skin infection at injection site
Intra-articular injection into an infected joint risks spreading infection and worsening outcomes.
Bleeding disorders or anticoagulant therapy
Intra-articular injection carries haemarthrosis risk in patients with coagulopathy.